OpGen (OPGN) Stock Forecast, Price & News

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OpGen in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" OpGen stock.
View analyst ratings for OpGen or view top-rated stocks.

3 analysts have issued 12-month target prices for OpGen's stock. Their OPGN stock forecasts range from $1.25 to $3.00. On average, they anticipate OpGen's share price to reach $2.13 in the next twelve months. This suggests a possible upside of 242.7% from the stock's current price.
View analysts' price targets for OpGen or view top-rated stocks among Wall Street analysts.

OpGen's stock was trading at $1.00 at the beginning of the year. Since then, OPGN shares have decreased by 38.0% and is now trading at $0.62.
View the best growth stocks for 2022 here.

OpGen is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for OpGen.

OpGen will be holding an earnings conference call on Thursday, August 11th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 412-317-6671 with passcode "13730742".

OpGen, Inc. (NASDAQ:OPGN) posted its quarterly earnings results on Thursday, May, 12th. The medical research company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.01. The medical research company had revenue of $0.47 million for the quarter, compared to analyst estimates of $1.05 million. OpGen had a negative net margin of 680.36% and a negative trailing twelve-month return on equity of 72.67%.

OpGen shares reverse split before market open on Friday, January 19th 2018. The 1-25 reverse split was announced on Wednesday, January 17th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 18th 2018. An investor that had 100 shares of OpGen stock prior to the reverse split would have 4 shares after the split.

OpGen issued an update on its second quarter 2022 earnings guidance on Friday, July, 29th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.00 million-$1.00 million, compared to the consensus revenue estimate of $950.00K.

Based on aggregate information from My MarketBeat watchlists, some companies that other OpGen investors own include Anavex Life Sciences (AVXL), Sorrento Therapeutics (SRNE), Energy Transfer (ET), Vaxart (VXRT), VBI Vaccines (VBIV), Nabriva Therapeutics (NBRV), SCYNEXIS (SCYX), Agile Therapeutics (AGRX), Pfizer (PFE) and Inovio Pharmaceuticals (INO).

(OPGN) raised $17 million in an initial public offering (IPO) on Tuesday, May 5th 2015. The company issued 2,900,000 shares at $5.50-$6.50 per share. Maxim Group acted as the underwriter for the IPO and National Securities was co-manager.

OpGen trades on the NASDAQ under the ticker symbol "OPGN."

Shares of OPGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of OPGN stock can currently be purchased for approximately $0.62.

OpGen (NASDAQ:OPGN) has a market capitalization of $28.87 million and generates $4.31 million in revenue each year. The medical research company earns $-34,810,000.00 in net income (profit) each year or ($0.85) on an earnings per share basis.

OpGen employs 91 workers across the globe.

OpGen's mailing address is 708 QUINCE ORCHARD ROAD SUITE 205, GAITHERSBURG MD, 20878. The official website for OpGen is www.opgen.com. The medical research company can be reached via phone at (240) 813-1260, via email at investorrelations@opgen.com, or via fax at 301-869-9684.